FINANCE ROUNDUP: Global Blood Doubles Post-IPO, GlobeImmune Considers Options, VC Deals Surge
This article was originally published in Scrip
Executive Summary
Global Blood Therapeutics launched an initial public offering at $20 per share and its stock price more than doubled to $43.11 at the end of its first day of trading on Aug. 12, proving that investors may be concerned about a biotechnology bubble, but they're not overly worried that it will burst soon.
You may also be interested in...
Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Finance Watch: Summer Slowdown Begins Ahead Of BIO, But Two IPOs Launched
Athenex and Immuron launched IPOs in the US, but June has otherwise been a pretty quiet month for new biopharma financings – so far. The largest VC round so far this month is Checkmate's $27m Series B and the biggest public offering was conducted by CTI BioPharma, raising $45m.
venBio's $315m Pharma-Backed Fund Seeks Broad Range Of Investments
VenBio has $315m in new cash to invest in a broad array of therapeutics developers now that it has closed its second venture capital fund, which raised $65m more than the VC firm originally intended and reflects big pharma's increasing commitment to backing early-stage life science companies.